Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-beta in macrophages

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Mausberg, Anne K ^a   Meyer zu Hörste, Gerd ^a   Dehmel, Thomas ^a   Stettner, Mark ^a   Lehmann, Helmar C ^a   Sheikh, Kazim A ^b   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD68 ANTIGEN; ERYTHROPOIETIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; EXPERIMENTAL RAT; FEMALE; GUILLAIN BARRE SYNDROME; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MYELIN SHEATH; NEURITIS; NONHUMAN; PERIPHERAL NERVE; PROTEIN LOCALIZATION; RAT; RISK REDUCTION; T LYMPHOCYTE; TISSUE DISTRIBUTION; UPREGULATION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; INFLAMMATION; METABOLISM; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

ANIMALIA; RATTUS;

ANIMALS; CYTOKINES; ERYTHROPOIETIN; INFLAMMATION; MACROPHAGES; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; RATS; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 80054769819     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026280     Document Type: Article

References (36)

1. Hughes RA, Swan AV, Raphael JC, Annane D, van KR, et al. (2007) Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 130: 2245-2257.
2. van KR, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, et al. (2007) A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 6: 589-594.
3. Griffin JW, Sheikh KA, (2005) The Guillain-Barré Syndromes. In: Dyck PJ, Thomas PK, editors. Peripheral Neuropathy Philadelphia Elsevier Saunders pp. 2197-2220.
4. King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, et al. (2007) Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol 205: 48-55.
5. Meyer zu Horste G, Hartung HP, Kieseier BC, (2007) From bench to bedside-experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 3: 198-211.
6. Brines M, Cerami A, (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6: 484-494.
7. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952: 128-134.
8. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, et al. (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198: 971-975.
9. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495-505.
10. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, et al. (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130: 2577-2588.
11. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101: 14907-14912.
12. Jelkmann W, (2007) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78: 183-205.
13. Brines M, Cerami A, (2006) Erythropoietin in spinal cord injury. In: Hoeke A, editors. Erythropoietin and the nervous system. Novel therapeutic options for neuroprotection New York Springer pp. 147-164.
14. Shaheen M, Broxmeyer HE, (2009) The humoral regulation of hematopoiesis. In: Hoffmann R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, editors. Hematology: Basic Principles and Practice Philadelphia Elsevier Churchill Livingston pp. 253-275.
15. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98: 4044-4049.
16. Yuan R, Maeda Y, Li W, Lu W, Cook S, et al. (2008) Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One 3: e1924.
17. Nairz M, Schroll A, Moschen AR, Sonnweber T, Theurl M, et al. (2011) Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways. Immunity 34: 61-74.
18. Gordon S, (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
19. Kiefer R, Kieseier BC, Bruck W, Hartung HP, Toyka KV, (1998) Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. Brain 121 (Pt 3): 469-479.
20. Kiefer R, Kieseier BC, Stoll G, Hartung HP, (2001) The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64: 109-127.
21. Craggs RI, King RH, Thomas PK, (1984) The effect of suppression of macrophage activity on the development of experimental allergic neuritis. Acta Neuropathol 62: 316-323.
22. Jung S, Huitinga I, Schmidt B, Zielasek J, Dijkstra CD, et al. (1993) Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci 119: 195-202.
23. Mueller M, Leonhard C, Wacker K, Ringelstein EB, Okabe M, et al. (2003) Macrophage response to peripheral nerve injury: the quantitative contribution of resident and hematogenous macrophages. Lab Invest 83: 175-185.
24. Bommireddy R, Doetschman T, (2007) TGFbeta1 and Treg cells: alliance for tolerance. Trends Mol Med 13: 492-501.
25. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, et al. (2004) TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 172: 834-842.
26. Johns LD, Sriram S, (1993) Experimental allergic encephalomyelitis: neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease. J Neuroimmunol 47: 1-7.
27. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA, (2004) TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 101: 4572-4577.
28. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, et al. (1992) Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89: 7375-7379.
29. Askenasy N, Kaminitz A, Yarkoni S, (2008) Mechanisms of T regulatory cell function. Autoimmun Rev 7: 370-375.
30. Wynn TA, Barron L, (2010) Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 30: 245-257.
31. Kiefer R, Funa K, Schweitzer T, Jung S, Bourde O, et al. (1996) Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. Am J Pathol 148: 211-223.
32. Jung S, Toyka KV, Hartung HP, (1995) Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci Lett 200: 167-170.
33. Kadlubowski M, Hughes RA, (1980) The neuritogenicity and encephalitogenicity of P2 in the rat, guinea-pig and rabbit. J Neurol Sci 48: 171-178.
34. Kieseier BC, Krivacic K, Jung S, Pischel H, Toyka KV, et al. (2000) Sequential expression of chemokines in experimental autoimmune neuritis. J Neuroimmunol 110: 121-129.
35. Lehmann HC, Lopez PH, Zhang G, Ngyuen T, Zhang J, et al. (2007) Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci 27: 27-34.
36. Fortier AH, Falk LA, (2001) Isolation of murine macrophages. Curr Protoc Immunol pp. 14.1.1-14.1.9.